Destination
Japan
- Latest exports
- $134.2M
- Market share
- 35%
- Growth
- +363.6%
- Access
- FTA reported
- Signal
- Accelerating
T3 · Product exporter position
France exports of Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) (HS 300390)
See where France stands in medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale): export scale, destination breadth, market position, growth, and reported trade history.
Latest exports
$466.2MLatest observed lane totalDestination markets
120Reported active marketsThree-year growth
+27.3%Annualized changeDestination HHI
1,595Destination concentrationWeighted share
28.3%Reported market positionExporter evidence
How strong is France in Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale)?
Reported exporter totals and calculated indicators for HS 300390. Values retain their observed coverage period.
Exporter scale
Latest exports$466.2M
Current 2024 exports$465.6M
Three-year average$332.9M
Historical peak$1.5B
Market position
Active destinations120
Destination HHI1,595
Weighted share28.3%
Share change+9.4 pp
Competitiveness
Three-year growth+27.3%
Volatility1.5
Maximum drawdown92.7%
TrendRapid growth
| Measure | Value | What it describes |
|---|---|---|
| Exporter | France | Country represented by this profile |
| Latest observed exports | $466.2M | Sum of latest observed destination-lane values |
| Current 2024 exports | $465.6M | Common-year comparison where reported |
| Three-year growth | +27.3% | Annualized change in exporter totals |
| Five-year growth | +7.6% | Annualized change in exporter totals |
| Leading destination | JPN | Destination with the largest observed export value |
| Leading destination share | 28.8% | Share of observed exporter totals |
| Destination concentration | 1,595 | HHI across destination markets |
| Weighted share change | +9.4 pp | Value-weighted latest change in market share |
| Limited-history lanes | 10.5% | Share of lanes with shorter history |
Destination markets
Where does France sell medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale)?
Leading destination observations ranked by reported export value, with market position and access context.
| Destination | Latest exports | Market share | Growth | Access | Signal |
|---|---|---|---|---|---|
| Japan | $134.2M | 35% | +363.6% | FTA reported | Accelerating |
| China | $107.4M | 25.4% | +43.2% | 0.3% tariff | Accelerating |
| Algeria | $56.8M | 56.8% | +20% | FTA reported | Accelerating |
| Iran (Islamic Republic of) | $23.0M | 48.9% | -0.3% | 0.6% tariff | Growing |
Destination
China
- Latest exports
- $107.4M
- Market share
- 25.4%
- Growth
- +43.2%
- Access
- 0.3% tariff
- Signal
- Accelerating
Destination
Algeria
- Latest exports
- $56.8M
- Market share
- 56.8%
- Growth
- +20%
- Access
- FTA reported
- Signal
- Accelerating
Destination
Iran (Islamic Republic of)
- Latest exports
- $23.0M
- Market share
- 48.9%
- Growth
- -0.3%
- Access
- 0.6% tariff
- Signal
- Growing
Price intelligence
How does France's price position vary?
Price comparisons are shown where market-level unit-value observations are available. They describe reported trade values and quantities, not quoted selling prices.
Highest reported price
New Zealand: $100.8M / ton.
Lowest reported price
United Rep. of Tanzania: $57.2 / ton.
Median price
$50.0K / ton across reported markets.
Export trend
Reported export history
Annual observations for France and HS 300390 where available.
| Year | Exports | Year-on-year change | Active destinations |
|---|---|---|---|
| 2010 | $284.3M | -17.5% | 132 |
| 2011 | $330.1M | +16.1% | 124 |
| 2012 | $313.3M | -5.1% | 125 |
| 2013 | $296.9M | -5.2% | 128 |
| 2014 | $294.3M | -0.9% | 125 |
| 2015 | $277.4M | -5.8% | 123 |
| 2016 | $252.1M | -9.1% | 128 |
| 2017 | $219.2M | -13.1% | 121 |
| 2018 | $293.6M | +33.9% | 117 |
| 2019 | $322.1M | +9.7% | 124 |
| 2020 | $346.2M | +7.5% | 136 |
| 2021 | $225.5M | -34.9% | 130 |
| 2022 | $230.9M | +2.4% | 124 |
| 2023 | $302.4M | +31% | 120 |
| 2024 | $465.6M | +54% | 120 |
Exporter context
France economy and trade network
The exporter profile adds country-level trade and structural context to the selected product position. These indicators describe the country overall and are not limited to HS 300390.
France has reported exports of $635.3B and a trade balance of -$95.5B in 2024.
Available structural indicators include 42.5% trade openness, 23.5% investment, and 270 active trade partners.
Reported values
Export totals and destination values describe reported merchandise trade for the stated exporter, HS6 classification, and available year.
Calculated indicators
Growth, concentration, weighted share, volatility, drawdown, and price comparisons are calculated from reported observations.
Coverage
Missing values remain “Not reported”. Country-level indicators are presented separately from product-level observations.
Frequently asked questions
Questions about France medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) exports
Quick answers based on the figures and coverage shown on this page.
How strong is this exporter?+
Use latest exports, destination breadth, growth, concentration, and weighted share together rather than relying on one measure.
Which markets are most important?+
The destination table ranks reported markets by the latest observed export value.
Does the price section show quotes?+
No. It summarizes reported trade value and quantity observations converted to unit values.
What should be checked next?+
Compare this exporter with buyer markets, corridors, and the product overview before making a commercial decision.